In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model
Fig 2
Simulated time course of selected cancer cell populations.
(A) Various tumor cell populations as a function of time in the case of free tumor growth. A homogeneous spherical tumor of 10mm diameter is considered. The values of code input parameters that regulate tumor growth kinetics are given in Table 5 (Squamous Cell Carcinoma—SCC representative case). (B) Various tumor cell populations as a function of time in the case of treatment response. A homogeneous spherical tumor of 10mm diameter is considered. A cell cycle specific (gemcitabine) and a cell cycle non-specific (cisplatin) drug are administered as a three-week cycle. Gemcitabine is given on days 7, 14, 28, 35, 49, 56. Cisplatin is administered on days 7, 28 and 49. After each chemotherapeutic session a drop in the various tumor cell populations is observed, followed by tumor repopulation. The values of code input parameters are given in Table 5 (Squamous Cell Carcinoma—SCC representative case). Abbreviations: DIFF: terminally DIFFerentiated tumor cell, G0: dormant, resting phase.